Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Anuh Pharma's net profit margin of 7.2% in FY2025 reflects thin profitability, with operating margin at 7.9% and gross margin at 24.5%.
In FY 2025, Anuh Pharma posted a gross margin of 24.5%, an operating margin of 7.9%, a net margin of 7.2%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Anuh Pharma's revenue grew 2.2% to 6.62B in FY2025, but net profit declined 21.2% to 473.52M — indicating margin compression.
In FY 2025, Anuh Pharma's revenue grew by 2.2% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Anuh Pharma's ROE of 14.5% in FY2025 indicates moderate shareholder returns.
In FY 2025, Anuh Pharma reported an ROE of 14.5%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Anuh Pharma's FCF/NI ratio of 0.36x in FY2025 indicates weak cash generation raising concerns about earnings quality.
In FY 2025, Anuh Pharma's free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Anuh Pharma's OCF/NI ratio of 0.78x in FY2025 indicates reasonable cash conversion from operations.
In FY 2025, Anuh Pharma's operating cash flow trailed net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Anuh Pharma's current ratio of 2.11x in FY2025 indicates healthy short-term liquidity.
In FY 2025, Anuh Pharma reported a current ratio of 2.11. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Anuh Pharma's interest coverage ratio of 84.2x in FY2025 indicates comfortable debt servicing capacity.
In FY 2025, Anuh Pharma reported an interest coverage ratio of 84.2x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Anuh Pharma's debt-to-equity ratio of 0.03x in FY2025 reflects a conservative, low-leverage capital structure.
In FY 2025, Anuh Pharma reported a debt-to-equity ratio of 0.03. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Anuh Pharma's debt increased 304.3% YoY in FY2025 — rising leverage demands close monitoring.
In FY 2025, Anuh Pharma's total debt increased by 304.3% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Anuh Pharma's diluted shares remained virtually unchanged in FY2025.
Over 2 years (FY2024–FY2025), diluted shares remained essentially unchanged at 100.22M.
In FY 2025, Anuh Pharma's diluted shares remained flat by 0.0% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025